₹874.55
▲ 1.46%
Delayed · as of 18 Aug 2026
Next dividend · FINAL · ₹2.00 per share
in 27 daysOwn the shares at the close of 11 Sep 2026 and ₹2.00 per share is yours.
Buying on 15 Sep 2026 is too late. Selling on or after 15 Sep 2026 does not cost you the payout — entitlement is fixed once the share goes ex.
The payment date is not published in the exchange feed. Companies usually credit the money within a few weeks of the record date.
- Ex-date
- 15 Sep 2026
- Record date
- 15 Sep 2026
Dividend per share by financial year
| Financial year | Total dividend |
|---|---|
| FY24 | ₹2.00 |
| FY25 | ₹3.50 |
| FY26 | ₹4.00 |
| FY27 | ₹2.00 |
Recent payouts
6 on record since FY24| Type | Amount | Ex-date | Record date | FY |
|---|---|---|---|---|
| FINAL | ₹2.00 | 15 Sep 2026 | ||
| INTERIM | ₹1.50 | 16 Feb 2026 | ||
| FINAL | ₹2.50 | 15 Sep 2025 | ||
| INTERIM | ₹2.50 | 14 Feb 2025 | ||
| FINAL | ₹1.00 | 31 Jul 2024 |
Against the marketIndex yields as of 17 Aug 2026+ Show– Hide
Index dividend yields are published by NSE alongside the closing levels. The dividend index is the fairer comparison: measured against the broad market almost every instrument here looks generous. A higher yield is not automatically better — it can mean a falling price as easily as a rising payout, which is what the chart above separates.
Yield through time
253 sessions · 07 Aug 2025 – 18 Aug 2026Trailing twelve-month payout divided by that session’s closing price, so a move here is either the payout changing or the price changing — the two readings a single current yield cannot tell apart. Ranged 0.27% to 0.74% over this window, ending at 0.46%. Closes and payouts are both split-adjusted, so a split does not appear as a change in yield. Tap or drag the chart to read a single session.
Others in Pharmaceuticals6 instruments+ Show– Hide
Ranked by published trailing-12-month yield. Classification is factual, not a recommendation.
Similar current yields
Same asset type, ordered by distance from this instrument’s published trailing-12-month yield. These are not business-sector peers or recommendations.